NKGen Biotech, Inc.
NKGN
$0.02
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.62% | -8.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.87% | -8.97% | |||
| Operating Income | 24.87% | 8.97% | |||
| Income Before Tax | -545.00% | 141.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -545.80% | 141.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -545.80% | 141.01% | |||
| EBIT | 24.87% | 8.97% | |||
| EBITDA | 25.97% | 9.38% | |||
| EPS Basic | -424.81% | 134.02% | |||
| Normalized Basic EPS | -2.55% | 67.89% | |||
| EPS Diluted | -582.96% | 122.92% | |||
| Normalized Diluted EPS | -45.48% | 77.37% | |||
| Average Basic Shares Outstanding | 37.24% | 20.54% | |||
| Average Diluted Shares Outstanding | -3.26% | 71.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||